Drug Profile
Research programme: muscular atrophy therapeutics - Rigel
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action Myostatin inhibitors; Type II activin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Muscular atrophy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Muscle-wasting in USA (IV)
- 04 Jan 2013 Preclinical trials in Muscular atrophy in USA (IV)